Adsorptive cytapheresis in ulcerative colitis: A non-pharmacological therapeutic approach revisited
- PMID: 37787399
- DOI: 10.1002/jca.22091
Adsorptive cytapheresis in ulcerative colitis: A non-pharmacological therapeutic approach revisited
Abstract
Adsorptive cytapheresis proves effective in a proportion of patients affected by ulcerative colitis. Relatively high cost and the need for apheresis facilities, prevented the widespread use of this therapeutic approach. More so following the introduction of anti-TNFα biosimilars which proved both effective and inexpensive. Anti-TNFα agents, however, are burdened by high rate of primary and secondary non-response and prompt switching to new, high-cost biologics, and small molecules. The present review analyzes advantages and disadvantages of adsorptive cytapheresis in the present clinical scenario and suggests its repositioning in the therapeutic workup of selected subgroups of ulcerative colitis patients. The extremely favorable safety profile makes adsorptive cytapheresis a viable therapeutic option in elderly and high-risk UC patients, as well as potential second-line treatment in corticosteroid-dependent patients and poor responders to first-line biologics.
Keywords: adsorptive cytapheresis; efficacy; inflammatory bowel diseases; mechanisms of action; safety; side effects; ulcerative colitis.
© 2023 The Authors. Journal of Clinical Apheresis published by Wiley Periodicals LLC.
References
REFERENCES
-
- Jørgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NORSWITCH): a 52-week, randomised, doubleblind, non-inferiority trial. Lancet. 2017;389:2304-2316.
-
- Habermalz B, Sauerland S. Clinical effectiveness of selective granulocyte, monocyte adsorptive apheresis with the Adacolumn device in ulcerative colitis. Dig Dis Sci. 2010;55:1421-1428.
-
- Fukuda Y, Matsui T, Suzuki Y. Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study. J Gastroenterol. 2004;39:1158-1164.
-
- Gubatan J, Keyashian K, Rubin SJS, Wang J, Buckman CA, Sinha S. Anti-integrins for the treatment of inflammatory bowel disease: current evidence and perspectives. Clin Exp Gastroenterol. 2021;14:333-342.
-
- Moschen AR, Tilg H, Raine T. IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nat Rev Gastroenterol Hepatol. 2019;16:185-196.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
